SharePains by Pieter Veenstra on MSN

CountRows, CountIf, CountA and Count in Power Apps

How often would you like to count the number of records without really wanting to load all the records that exist in a list ...

Build Faster Excel Workflows Using FILTER, IFS, XLOOKUP, and LET for Real-World Data

Learn the difference between Excel COUNT and COUNTA, plus TEXTBEFORE and TEXTAFTER tricks, so you clean text and totals with ...
BioSpace

FDA Minutes Confirm Challenging Path Ahead for UniQure’s Huntington’s Gene Therapy

The past four months have been a rollercoaster ride for uniQure—and for patients with Huntington’s, a genetic, neurodegenerative disease. On Sept. 24, uniQure reported three-year data from a pivotal ...
Bloomberg L.P.

UniQure Tumbles After ‘Surprising’ Pivot by FDA on Drug Data

UniQure NV plunged Monday after the drug developer said US regulators deemed the clinical data for its experimental gene-therapy for Huntington’s disease as insufficient. The Amsterdam-based company ...
FierceBiotech

uniQure's ballyhooed gene therapy for Huntington's hits FDA roadblock

The FDA is said to be making a U-turn on uniQure’s one-time gene therapy candidate for Huntington’s disease despite the treatment being hailed as a game changer. The FDA no longer agrees that data ...
Seeking Alpha

uniQure: Further Upside Likely As The Opportunity Becomes Better Understood

uniQure surged over 300% following strong 3-year data from its Huntington’s trial, yet remains undervalued due to skepticism over trial size and the use of external controls. AMT-130’s apparent ...
Reuters

UniQure's therapy slows Huntington's disease progression in trial

Sept 24 (Reuters) - UniQure's (UQ1.F), opens new tab experimental gene therapy for Huntington's disease slowed progression of the brain disorder by 75% in an early-to-mid stage study, it said on ...
Seeking Alpha

uniQure: Price And Value Have Caught Up

When I last valued uniQure in January 2024, I estimated its intrinsic worth at $33 per share, while the stock was trading in the $6 range. This implied a discount of over 80%, underscoring the ...
Nasdaq

uniQure N.V. Appoints Kylie O’Keefe as Chief Customer and Strategy Officer to Drive AMT-130 Commercialization in Huntington’s Disease

uniQure appoints Kylie O’Keefe as Chief Customer and Strategy Officer to lead AMT-130's commercialization for Huntington's disease. uniQure N.V. has appointed Kylie O’Keefe as Chief Customer and ...